Compare JFR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFR | PCRX |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2004 | 2010 |
| Metric | JFR | PCRX |
|---|---|---|
| Price | $7.24 | $36.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $33.57 |
| AVG Volume (30 Days) | 904.7K | ★ 2.2M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $3.84 |
| Revenue Next Year | N/A | $4.73 |
| P/E Ratio | ★ N/A | $191.47 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $7.09 | $18.80 |
| 52 Week High | $8.00 | $36.67 |
| Indicator | JFR | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 83.12 |
| Support Level | $7.23 | $21.97 |
| Resistance Level | $7.64 | $36.67 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | -0.23 |
| Stochastic Oscillator | 44.55 | 27.40 |
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.